BACKGROUND: Between January 1999 and December 2008, 469 patients treated for acute myeloid leukemia (AML) were included in this single-institution study. METHODS: We performed a case-control analysis to study the rate of obesity among patients with acute promyelocytic leukemia (APL) and non-APL AML. RESULTS: A total of 81% of APL patients analyzed were obese compared with 41.7% in the non-APL group (p < 0.001). Body mass index (BMI) >30 was seen in 57% of APL patients compared with 31% for the non-APL group (p = 0.01). Neither obesity nor the chemotherapy dosing based on ideal body weight affected survival. CONCLUSIONS: Our findings generate the hypothesis that APL and metabolic syndromes may share a common pathogenic pathway via retinoic acid receptors (RARs), the ligand-controlled transcription factors that function as heterodimers with retinoid X receptors (RXRs) to regulate cell growth and survival. If this link is confirmed in larger studies, our data will instigate further studies using RXR and RAR modulators as a preventive strategy among obese individuals.
BACKGROUND: Between January 1999 and December 2008, 469 patients treated for acute myeloid leukemia (AML) were included in this single-institution study. METHODS: We performed a case-control analysis to study the rate of obesity among patients with acute promyelocytic leukemia (APL) and non-APLAML. RESULTS: A total of 81% of APLpatients analyzed were obese compared with 41.7% in the non-APL group (p < 0.001). Body mass index (BMI) >30 was seen in 57% of APLpatients compared with 31% for the non-APL group (p = 0.01). Neither obesity nor the chemotherapy dosing based on ideal body weight affected survival. CONCLUSIONS: Our findings generate the hypothesis that APL and metabolic syndromes may share a common pathogenic pathway via retinoic acid receptors (RARs), the ligand-controlled transcription factors that function as heterodimers with retinoid X receptors (RXRs) to regulate cell growth and survival. If this link is confirmed in larger studies, our data will instigate further studies using RXR and RAR modulators as a preventive strategy among obese individuals.
Entities:
Keywords:
RAR; RXR; acute promyelocytic leukemia; body mass index; obesity; prevention
Authors: F Grignani; S De Matteis; C Nervi; L Tomassoni; V Gelmetti; M Cioce; M Fanelli; M Ruthardt; F F Ferrara; I Zamir; C Seiser; F Grignani; M A Lazar; S Minucci; P G Pelicci Journal: Nature Date: 1998-02-19 Impact factor: 49.962
Authors: Miguel A Sanz; David Grimwade; Martin S Tallman; Bob Lowenberg; Pierre Fenaux; Elihu H Estey; Tomoki Naoe; Eva Lengfelder; Thomas Büchner; Hartmut Döhner; Alan K Burnett; Francesco Lo-Coco Journal: Blood Date: 2008-09-23 Impact factor: 22.113
Authors: Lucia Altucci; Mark D Leibowitz; Kathleen M Ogilvie; Angel R de Lera; Hinrich Gronemeyer Journal: Nat Rev Drug Discov Date: 2007-10 Impact factor: 84.694
Authors: Hun Ju Lee; Andrea S Licht; Andrew J Hyland; Laurie A Ford; Sheila N J Sait; Annemarie W Block; Maurice Barcos; Maria R Baer; Eunice S Wang; Meir Wetzler Journal: Ann Hematol Date: 2011-09-21 Impact factor: 3.673
Authors: John W R Kincaid; Gretchen Weiss; Anne E Hill-Baskin; Heidi M Schmidt; Ovwoioise Omoijuanfo; Cheryl L Thompson; Rose C Beck; Nathan A Berger Journal: Obesity (Silver Spring) Date: 2022-05-24 Impact factor: 9.298
Authors: Kathryn L Laurie; Paul Lee; Alfred Rademaker; Todd A Alonzo; Yi-Cheng Wang; Bayard L Powell; Diana Wu; Richard Larson; Matthew Kutny; John Gregory; Nobuko Hijiya; James Feusner Journal: Pediatr Blood Cancer Date: 2022-03-24 Impact factor: 3.838
Authors: Simone Ummarino; Clinton Hausman; Giulia Gaggi; Lucrezia Rinaldi; Mahmoud A Bassal; Yanzhou Zhang; Andy Joe Seelam; Ikei S Kobayashi; Marta Borchiellini; Alexander K Ebralidze; Barbara Ghinassi; Bon Q Trinh; Susumu S Kobayashi; Annalisa Di Ruscio Journal: Cells Date: 2021-11-02 Impact factor: 7.666